12:00 AM
Nov 04, 2002
 |  BioCentury  |  Product Development

MDX-010 goes it alone

The case for using Medarex Inc.'s MDX-010 antibody in combination cancer therapy has a sound rationale: The antibody blocks negative regulation of T cells, allowing an active immune response elicited by tumor vaccine therapy to continue unabated. But Medarex Inc. is betting that the compound also can bring to life the paltry anti-tumor immune responses that occur naturally in cancer patients.

Last week, the company began two Phase II trials of the anti-CTLA-4 antibody as monotherapy, one in metastatic melanoma and the other in hormone refractory prostate cancer.

MDX-010 already is in Phase II development in combination with tumor vaccines. A Phase II trial is...

Read the full 520 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >